Inotiv, Inc. announced an agreement to partner with Japan-based PhoenixBio Co., Ltd., to provide research services in Inotiv's U.S. labs using PhoenixBio's proprietary PXB-mouse® research model, a liver-humanized chimeric model used for drug discovery and early development. This collaboration enhances the Inotiv portfolio and leverages the Company's extensive experience and expertise working with liver-humanized chimeric research models to enable and advance important translational research for hepatic diseases, as well as cell and gene therapy approaches where liver engagement is a key endpoint. PhoenixBio's PXB-mouse® has been the most utilized liver-humanized research model, with growing demand across a range of applications including drug metabolism and pharmacokinetics (DMPK), toxicology, and other pharmacology-related evaluations.